Nurix Therapeutics (NRIX)
NASDAQ:NRIX
NRIX Stock Chart & Stats
$16.03
$0.42(2.22%)
At close: 4:00 PM EST
$16.03
$0.42(2.22%)
Day’s Range― - ―
52-Week Range$8.20 - $22.50
Previous CloseN/A
Volume302.00K
Average Volume (3M)1.24M
Market Cap
$1.66B
Enterprise Value$1.38B
Total Cash (Recent Filing)$540.73M
Total Debt (Recent Filing)$58.66M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Jul 09, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding103,405,815
10 Day Avg. Volume1,256,275
30 Day Avg. Volume1,242,880
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue19.18
Enterprise Value/Gross Profit-13.76
Enterprise Value/Ebitda-4.76
Forecast
1Y Price Target
$30.82Price Target Upside92.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3
Revenue Forecast (FY)$57.91M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressAdvancing enrollment in the pivotal DAYBreak CLL study and planning a confirmatory head-to-head Phase 3 trial against a leading competitor supports a potential accelerated approval pathway and could meaningfully lift valuation if clinical results are favorable.
Partnerships And Milestone PotentialA partnered STAT6 degrader program with a large pharmaceutical company, together with prior collaboration deals that included upfront payments and milestone upside, provides external validation and the potential for milestone payments that could boost the stock.
Scientific ValidationOral and poster presentations at a major cancer research conference that highlight Nurix's degrader programs and CBL-B research may strengthen scientific credibility and increase investor interest in pipeline prospects.
Bears Say
Clinical Proof-of-concept RiskNegative clinical proof-of-concept for a lead candidate such as NX-2127, NX-5948, or NX-1607 would materially undermine the pipeline narrative and could sharply reduce company value.
Execution And Regulatory RiskHeavy reliance on multiple pivotal trials and the need for timely regulatory approvals creates execution risk that can lead to binary outcomes and elevated share-price volatility.
Financial PerformanceLower-than-expected collaboration revenue and a wider GAAP net loss than analysts modeled weigh on near-term financial results and may put downward pressure on the share price.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $8.20 and its highest was $22.50 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Nurix Therapeutics’s market cap is $1.66B.
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Jul 09, 2026 which is in 87 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Apr 08, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.763 by -$0.027.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -0.73.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 103,405,815 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.763. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Currently, no hedge funds are holding shares in NRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.82 (92.26% Upside)
$30.82 (92.26% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.95%
12-Months-Change
Fundamentals
Return on Equity
-64.21%
Trailing 12-Months
Asset Growth
3.43%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
NRIX Stock 12 Month Forecast
Average Price Target
$30.82
▲(92.26% Upside)
Technical Analysis
Arvinas Holding Company
―
Vir Biotechnology
―
Relay Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
0.20% Insiders
15.52% Mutual Funds
58.06% Other Institutional Investors
5.16% Public Companies and
Individual Investors